Celsion sheds BPH microwave system
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific picks up Celsion's Prolieve microwave urethroplasty system for $60 million, Celsion announces April 18. Boston Scientific will pay $30 million at the close of the deal and two annual installments of $15 million. Boston Scientific began selling the Prolieve benign prostate hyperplasia treatment system in 2004 under a distribution agreement that had been set to expire in 2009 (1"The Gray Sheet" Feb. 23, 2004, p. 23). The sale of Prolieve completes Celsion's transition to an oncology focused drug company...
You may also be interested in...
Boston Scientific To Market Celsion’s Prolieve BPH Device Immediately
Boston Scientific will promote Celsion's Prolieve microwave urethroplasty system as a less-painful alternative to existing treatments for benign prostatic hyperplasia (BPH), following FDA approval Feb. 19
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.